Duodenal Ulcer Treatment Market By Treatment Type (Proton Pump Inhibitors, Potassium-Competitive Acid Blockers, H2-Receptor Antagonists, Bismuth-Based Quadruple Therapies, Rifabutin-Based Combination Therapies, Clarithromycin-Based Combination Therapies, Mucosal Protective Agents, Endoscopic Hemostasis, Surgical Treatment); By Application (Helicobacter pylori-Associated Duodenal Ulcers, NSAID-Induced Duodenal Ulcers, Recurrent Duodenal Ulcers, Bleeding Duodenal Ulcers, Perforated Duodenal Ulcers, Refractory Duodenal Ulcers); By End User (Hospitals, Gastroenterology Clinics, Ambulatory Endoscopy Centers, Diagnostic Laboratories, Retail Pharmacies, Hospital and Specialty Pharmacies); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Duodenal Ulcer Treatment Market: Antibiotic Resistance Shifts Prescribing Toward Bismuth, Rifabutin, and P-CAB Regimens

The Global Duodenal Ulcer Treatment Market was valued at USD 4.61 billion in 2025 and is projected to reach USD 7.50 billion by 2032, growing at a 7.2% CAGR, according to Strategic Market Research.

 

Eradication failure is becoming a more important commercial factor in the Duodenal Ulcer Treatment Market than changes in ulcer incidence. Generic proton pump inhibitors continue to account for most prescriptions, but low prices restrict revenue growth. Higher-value demand is shifting towards Helicobacter pylori eradication packs, potassium-competitive acid blockers, rifabutin-based combinations, resistance testing, confirmation testing, and hospital treatment for bleeding or perforation.

 

The 2024 guidelines from the American College of Gastroenterology have expedited this shift in prescribing practices by advocating for a 14-day optimized bismuth quadruple therapy in cases where antibiotic susceptibility is not known. For eligible patients, vonoprazan-amoxicillin dual therapy and rifabutin triple therapy are acknowledged as viable empirical alternatives, while clarithromycin triple therapy is typically reserved for infections confirmed to be susceptible. The adoption of these guidelines is steering expenditure away from low-cost but unreliable three-drug regimens and towards combinations that are designed to maintain effectiveness against resistant infections.

 

Successful eradication of H. pylori can eliminate the primary cause of a duodenal ulcer that tests positive for this bacterium. Consequently, treatment revenue is primarily focused on a limited course of antibiotics and acid suppression, followed by confirmation testing. Extended treatment durations are predominantly seen in patients who continue to use NSAIDs, do not achieve eradication, experience reinfection, or suffer from bleeding and perforation.

 

Active Ulcer Treatment Represents Only Part of the Global Infection Burden

The U.S. National Institute of Diabetes and Digestive and Kidney Diseases estimates that peptic ulcers affect approximately 1% to 6% of the U.S. population. The figure includes both gastric and duodenal disease, but it provides a more credible treatment base than historic lifetime-prevalence estimates that do not separate active, previously treated, and asymptomatic disease.

Global peptic-ulcer prevalence was estimated at approximately 8.09 million cases in 2019, representing a 25.82% increase from 1990. Population growth and ageing increased the absolute number of cases even as age-standardized rates declined in several higher-income markets. Prescription and procedure volume can therefore rise without a corresponding deterioration in disease control.

The global H. pylori population is substantially larger than the clinically treated ulcer population. A contemporary review estimated infection prevalence at approximately 43.9% among adults and 35.1% among children and adolescents during 2015–2022. Most infected individuals never develop an active duodenal ulcer, so applying infection prevalence directly to treatment forecasts would materially overstate demand.

Testing rates, symptom presentation, endoscopy access, previous antibiotic exposure, and local resistance determine how many infected patients reach treatment. Asia, Africa, and parts of Latin America carry substantial infection burdens but often have limited susceptibility testing and uneven access to confirmation testing. These conditions favour empiric regimens that remain effective across resistance patterns, although affordability limits uptake of premium branded combinations.

NSAID-associated disease creates a separate treatment population among older adults, arthritis patients, chronic-pain populations, and people using aspirin or other antiplatelet medicines. Patients who cannot discontinue the ulcerogenic drug may require longer acid suppression than those successfully treated for H. pylori infection.

 

Effective First-Line Eradication Reduces Repeat Treatment Spending

A Cochrane review covering 27 trials and 2,509 participants reported recurrent duodenal ulcer in 12.9% of patients after H. pylori eradication therapy, compared with 64.4% without eradication. The 51.5-percentage-point absolute reduction gives payers a clear reason to prioritize regimens capable of achieving bacterial cure during the first course.

The same evidence base found persistent duodenal ulcers in 12.4% of patients receiving eradication plus ulcer-healing therapy, compared with 18.7% among those receiving ulcer-healing treatment alone. Two smaller trials reported persistent ulceration in 21.7% after eradication therapy versus 58.5% without active treatment.

Much of the direct ulcer-healing evidence predates current resistance patterns, but acid suppression still does not address the main cause of recurrence in infected patients. Failed eradication leads to another physician visit, repeat testing, further antibiotic exposure, and a rescue regimen.

Fixed-dose or co-packaged regimens can support higher pricing when they improve eradication, adherence, and first-course success. Their value depends on reducing retreatment and the additional costs associated with failed therapy, rather than on the unit price of generic ingredients.

The ACG recommends documenting eradication in every treated patient with a urea breath test, stool antigen test, or biopsy-based method at least four weeks after antibiotics. PPIs and P-CABs should generally be stopped for at least two weeks before testing. Routine test-of-cure requirements support diagnostic laboratories, breath-test platforms, stool antigen assays, and follow-up gastroenterology services.

 

Clarithromycin Resistance Has Removed Empiric Triple Therapy from the Default Position

A global meta-analysis covering 178 studies, 66,142 isolates, and 65 countries found primary or secondary resistance of at least 15% to clarithromycin, metronidazole, and levofloxacin in nearly all WHO regions. Clarithromycin resistance increased the odds of eradication failure almost sevenfold, with an odds ratio of 6.97.

A more recent U.S. and European clinical-trial isolate analysis reported clarithromycin resistance in 22.2% of samples, metronidazole resistance in 69.2%, and amoxicillin resistance in only 1.2%. Low amoxicillin resistance preserves its position in vonoprazan dual therapy, rifabutin combinations, and other optimized regimens. Clarithromycin use increasingly depends on susceptibility results or a carefully reviewed antibiotic history.

The Pylera regulatory study quantified the risk of prescribing clarithromycin without resistance information. Clarithromycin triple therapy achieved 92.1% eradication in susceptible infections but only 21.4% in non-susceptible infections. A regimen that fails in almost four out of five resistant cases creates avoidable spending on repeat testing, rescue therapy, and additional clinical visits.

Culture-based and molecular resistance testing can improve regimen selection, but access remains limited in many community settings. Bismuth, rifabutin, and vonoprazan-amoxicillin combinations are gaining ground because physicians can use them without relying on clarithromycin susceptibility.

Diagnostic companies also benefit from the change in prescribing. Molecular assays that detect resistance mutations can support targeted antibiotic use, while urea breath tests and stool antigen assays confirm whether treatment succeeded. Better testing coverage reduces unnecessary repeat therapy and gives premium regimens a clearer outcome-based value proposition.

 

Bismuth Quadruple Therapy Gains Share Despite a Heavy Dosing Schedule

Optimized bismuth quadruple therapy combines a PPI, bismuth, tetracycline, and metronidazole for 14 days. The regimen has become the preferred empiric option because it avoids clarithromycin and can be used in selected patients with penicillin allergy.

European registry data show that guideline changes are translating into routine prescribing. Among 49,690 patients in the European Registry on H. pylori Management, 15,582, or 31%, received bismuth quadruple treatment. Its share increased from 8.6% in 2013 to 39% in 2021, indicating sustained replacement of conventional triple therapy.

Single-capsule bismuth quadruple therapy achieved approximately 92% modified intention-to-treat eradication in a large European real-world analysis. First-line effectiveness reached about 95%, while second-line and later-line treatment remained close to or above 89%. Compliance was the strongest factor associated with success.

Dosing complexity remains the main commercial weakness. Pylera requires three capsules four times daily, along with twice-daily omeprazole. Missed doses and early discontinuation can reduce the benefit of an otherwise effective regimen.

Fixed-dose packaging gives branded suppliers room to compete in a category built largely from generic ingredients. Co-packaging reduces prescribing errors and prevents omission of one component, although it does not eliminate the overall pill burden.

Tetracycline supply also affects market access. Shortages or local unavailability can push clinicians toward rifabutin or P-CAB-based alternatives. Suppliers with stable ingredient sourcing, clear dosing instructions, and adherence support are better positioned than companies competing only through price.

 

P-CABs Establish a Branded Acid-Suppression Segment

Potassium-competitive acid blockers provide faster and more consistent acid suppression than traditional PPIs. Their strongest economic role is within eradication regimens where sustained gastric pH can improve antibiotic performance, rather than as universal replacements for inexpensive generic PPIs.

The PHALCON-HP trial reported modified intention-to-treat eradication of 80.8% with vonoprazan-amoxicillin-clarithromycin, 77.2% with vonoprazan-amoxicillin dual therapy, and 68.5% with lansoprazole-amoxicillin-clarithromycin.

Among clarithromycin-resistant infections, eradication reached 65.8% with vonoprazan triple therapy and 69.6% with vonoprazan dual therapy, compared with 31.9% for the conventional PPI regimen. Removing clarithromycin gives the dual pack a stronger position in antimicrobial stewardship and resistance management.

Phathom Pharmaceuticals has built commercial infrastructure around vonoprazan in the United States. The company reported approximately 1.35 million cumulative Voquezna prescriptions by April 2026 and USD 58.3 million in first-quarter 2026 revenue, up 104% year over year. The figures include indications beyond H. pylori eradication, but they demonstrate increasing prescriber familiarity, payer coverage, and pharmacy availability for the P-CAB platform.

China has developed a direct P-CAB position in duodenal ulcer through keverprazan. Fosun Pharma and Jiangsu Carephar launched the product after Chinese approval for duodenal ulcer and reflux esophagitis in 2023. Subsequent inclusion in China’s National Reimbursement Drug List expanded access beyond a premium self-pay population.

Keverprazan-based quadruple therapy achieved 87.8% eradication in a Phase III full analysis set, compared with 82.5% for an esomeprazole-based regimen. Chinese approval, reimbursement, and eradication evidence give Fosun and Carephar a direct position in both ulcer healing and H. pylori management.

Daewoong’s fexuprazan and Onconic Therapeutics’ zastaprazan add competitive pressure across Asian acid-related disease markets. Their relevance to duodenal-ulcer forecasts depends on country-specific approvals and reimbursement rather than class-wide assumptions. A P-CAB approved only for reflux or gastritis should not be counted as established duodenal-ulcer revenue.

 

Rifabutin Combinations Provide a Resistance-Oriented Alternative

Rifabutin-based treatment gives clinicians a non-clarithromycin option when bismuth therapy is unavailable, unsuitable, or previously unsuccessful. The ERADICATE Hp trial reported 83.8% eradication with rifabutin, amoxicillin, and omeprazole, compared with 57.7% for omeprazole and amoxicillin. The 26.1-percentage-point difference supported FDA approval of RedHill Biopharma’s Talicia.

Talicia packages two antibiotics and a PPI into one regimen, although patients still take four capsules three times daily for 14 days. Low rifabutin and amoxicillin resistance provides the main advantage; dosing convenience is relative rather than absolute.

Commercial access expanded in January 2025 when Humana Part D coverage added more than eight million Medicare lives without a prior step or authorization requirement. RedHill also entered a U.S. co-commercialization agreement in late 2025, with joint activity beginning in February 2026.

International licensing provides another route to growth. RedHill has pursued regional expansion in the Middle East and a potential UK submission, allowing local partners to carry sales, regulatory, and reimbursement responsibilities.

Rifabutin use will remain more selective than bismuth treatment because of antibiotic-stewardship concerns, pricing, and the broader clinical importance of rifamycins. Strong positioning is most likely in rescue therapy, bismuth-intolerant patients, and selected first-line cases where clarithromycin should be avoided.

 

NSAID Exposure Preserves Longer-Term PPI Demand

Successful H. pylori eradication does not remove ulcer risk when patients continue an ulcerogenic NSAID. Among patients with previous ulcer bleeding who resumed naproxen, recurrent bleeding occurred in 18.8% after eradication alone, compared with 4.4% among those receiving continued omeprazole.

The 14.4-percentage-point reduction supports ongoing gastroprotection in high-risk NSAID users. Older adults with arthritis, cardiovascular disease, or chronic pain may remain on aspirin, naproxen, or other anti-inflammatory treatment for years, creating a more durable acid-suppression population than uncomplicated infection-driven ulcers.

Generic PPIs retain the strongest position in long-term prevention because chronic use is price sensitive. Broad formulary access and physician familiarity are more important than rapid onset for many patients.

P-CAB suppliers may target patients with recurrent ulceration, poor PPI adherence, nocturnal acid breakthrough, or previous bleeding. Premium pricing will require evidence that stronger acid control reduces repeat events or improves adherence enough to offset higher acquisition costs.

Ageing Asian populations may provide the clearest NSAID-prevention opportunity for regional P-CAB manufacturers. Expanded indications in NSAID-related ulcer prevention could extend product lifecycles beyond eradication and reflux treatment.

 

Bleeding and Perforation Concentrate Spending in Hospitals

Bleeding and perforation affect a minority of ulcer patients but generate substantially higher spending per case than routine eradication. Hospital treatment includes emergency assessment, endoscopy, anesthesia, transfusion, intravenous PPIs, intensive monitoring, embolization, and surgery.

The ACG recommends endoscopic therapy for ulcers with active spurting, active oozing, or a nonbleeding visible vessel. After successful hemostasis, patients receive high-dose PPI therapy for three days, followed by twice-daily oral treatment during early recovery.

Recurrent bleeding usually leads to repeat endoscopy. Failed endoscopic control can require transcatheter arterial embolization or surgery. Hospitals with continuous endoscopy and interventional-radiology coverage can manage more cases without open surgery, shifting expenditure toward endoscopic devices and embolic procedures.

Selection among clips, thermal probes, hemostatic powders, injection systems, and over-the-scope clips depends on lesion anatomy, bleeding severity, operator expertise, and rebleeding risk. Demand is tied to acute endoscopic case volume rather than overall duodenal-ulcer prevalence.

Perforation remains a major indication for emergency surgery despite the decline of elective acid-reducing operations. In selected patients, laparoscopic repair can shorten hospital stay and reduce postoperative morbidity, whereas delayed presentation, hemodynamic instability, large perforations, and limited surgical capacity still favor open repair.

 

Regional Growth Follows Resistance Patterns and Reimbursement

North America is moving toward bismuth, rifabutin, and vonoprazan regimens as the ACG guideline discourages empiric clarithromycin treatment. Growth depends on changing community prescribing, expanding test-of-cure rates, and improving payer access rather than increasing overall ulcer incidence.

Phathom’s rising Voquezna prescription volume and RedHill’s expanded Talicia coverage show that branded eradication products can gain adoption when reimbursement and commercial reach improve. Generic bismuth therapy still limits pricing power, so branded products must demonstrate simpler use, reliable cure, or stronger performance in resistant infection.

Europe provides the strongest real-world evidence of bismuth adoption through Hp-EuReg. Countries with stable bismuth and tetracycline supply can use optimized quadruple therapy broadly, while ingredient shortages create demand for single-capsule formulations or non-bismuth alternatives.

Asia combines high H. pylori prevalence with the strongest P-CAB development activity. Keverprazan’s Chinese approval and reimbursement, Phathom’s vonoprazan franchise, and Korean P-CAB expansion show that the class has progressed beyond experimental acid suppression into commercial treatment platforms.

Lower-income countries remain dependent on generic PPIs and antibiotics. Limited resistance testing, weak confirmation testing, and high out-of-pocket spending increase repeated treatment and antibiotic misuse. Affordable co-packaged regimens may generate more practical value in these markets than premium acid blockers.

 

Competitive Outlook

Generic PPI manufacturers will retain the largest unit volume, but low prices and limited product differentiation restrict revenue growth. Bismuth-combination suppliers benefit from guideline preference, resistance-robust performance, and increasing European adoption.

Phathom Pharmaceuticals holds the leading Western P-CAB position through Voquezna dual and triple packs. Rising prescriptions, revenue growth, and expanding payer access support the company’s position beyond a single product launch.

RedHill Biopharma has a differentiated rifabutin franchise through Talicia. Medicare coverage, U.S. co-commercialization, and international licensing provide several routes to expand uptake in patients requiring a non-clarithromycin regimen.

Fosun Pharma and Jiangsu Carephar have established keverprazan as a reimbursed Chinese P-CAB with direct duodenal-ulcer and H. pylori treatment relevance. Daewoong and Onconic Therapeutics add further Asian competition through fexuprazan and zastaprazan across acid-related indications.

Diagnostic providers gain as resistance and confirmation testing become routine parts of treatment. Urea breath tests, stool antigen assays, molecular resistance panels, pathology, and culture services influence regimen selection and determine whether patients need rescue therapy.

Duodenal-ulcer treatment growth will come primarily from replacing failed empiric therapy. Bismuth quadruple treatment will retain the strongest guideline-backed position when susceptibility is unknown. P-CAB combinations will gain where stronger acid suppression and simpler regimens justify premium pricing. Rifabutin combinations will serve patients requiring a non-clarithromycin alternative.

Therapies achieving over 90% real-world eradication, with sustained adherence and fewer rescue regimens, will hold greater clinical and commercial value than acid-suppression-only options. Revenue will depend more on test-of-cure uptake, resistance patterns, formulary access, fixed-dose packaging, and ingredient supply than on generic PPI pricing.

 

Duodenal Ulcer Treatment Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 4.61 Billion
Revenue Forecast in 2032	USD 7.50 Billion
Overall Growth Rate	CAGR of 7.2% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Treatment Type, By Application, By End User, By Geography
By Treatment Type	Proton Pump Inhibitors, Potassium-Competitive Acid Blockers, H2-Receptor Antagonists, Bismuth-Based Quadruple Therapies, Rifabutin-Based Combination Therapies, Clarithromycin-Based Combination Therapies, Mucosal Protective Agents, Endoscopic Hemostasis, Surgical Treatment
By Application	Helicobacter pylori-Associated Duodenal Ulcers, NSAID-Induced Duodenal Ulcers, Recurrent Duodenal Ulcers, Bleeding Duodenal Ulcers, Perforated Duodenal Ulcers, Refractory Duodenal Ulcers
By End User	Hospitals, Gastroenterology Clinics, Ambulatory Endoscopy Centers, Diagnostic Laboratories, Retail Pharmacies, Hospital and Specialty Pharmacies
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, Spain, China, Japan, South Korea, India, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	• Rising prevalence of Helicobacter pylori infections and peptic ulcer disorders • Increasing adoption of advanced acid suppression therapies and combination treatment approaches • Growing demand for minimally invasive ulcer management and improved gastrointestinal care infrastructure
Customization Option	Available upon request